# A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes

> **NCT01769404** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 25 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** LY2605541
- **BIOLOGICAL:** Insulin Glargine

## Key facts

- **NCT ID:** NCT01769404
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01769404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01769404, "A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01769404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*